SOLO-1
2018
Maintenance Olaparib in Newly Diagnosed BRCA-Mutated Advanced Ovarian Cancer
In 391 patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer in response to first-line platinum, maintenance olaparib for two years improved progression-free and overall survival compared with placebo.
Result
Efficacy: Progression-free survivalHR 0.3
Below 1 favours olaparib for two years, above 1 favours placebo.
Also reported: 7-yr OS HR 0.55; 7-yr OS 67.0% vs 46.5%.
- Subtopic
- BRCA-mutated ovarian
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Moore K, et al. N Engl J Med. 2018;379(26):2495-2505.doi 10.1056/NEJMoa1810858
Discussion & critique
Defined PARP-inhibitor maintenance as first-line standard in BRCA-mutated advanced ovarian cancer. PAOLA-1 extended this to the HRD-positive population on olaparib + bevacizumab.